<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03694938</url>
  </required_header>
  <id_info>
    <org_study_id>DEMECIA</org_study_id>
    <nct_id>NCT03694938</nct_id>
  </id_info>
  <brief_title>Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients</brief_title>
  <official_title>Dépistage Des métastases cérébrales Par IRM Chez Les Patients Avec un adénocarcinome Colorectal métastatique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to prospectively determine the incidence of brain metastases in
      metastatic colorectal cancer patients using systematic annual screening by MRI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2019</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prospectively determine the incidence of brain metastases in metastatic colorectal cancer patients with annual MRI.</measure>
    <time_frame>3 years</time_frame>
    <description>Diagnostic of brain metastases on annual MRI</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Magnetic resonance imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Annual MRI during 3 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic resonance imaging</intervention_name>
    <description>Annually magnetic resonance imaging</description>
    <arm_group_label>Magnetic resonance imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven colorectal adenocarcinoma

          -  Metastases from colorectal cancer diagnosed since less than 3 months

          -  Indication of an oncologic treatment

        Exclusion Criteria:

          -  Patient with contraindication for MRI

          -  Diagnosis of cancer other than colorectal cancer in the last three years, except in
             situ cancers, basal-cell skin cancer or squamous-cell skin cancer, and other cancer
             with low risk of brain dissemination according to the investigator

          -  Pregnant or breastfeeding women, women of childbearing potential without effective
             contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David TOUGERON, MD, PhD</last_name>
    <phone>0549443751</phone>
    <phone_ext>+33</phone_ext>
    <email>david.tougeron@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>C.H.U. de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Tougeron, MD</last_name>
      <email>david.tougeron@chu-poitiers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>December 17, 2019</last_update_submitted>
  <last_update_submitted_qc>December 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brain metastasis</keyword>
  <keyword>Magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

